ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TYR Tyratech (DI/S)

2.95
0.00 (0.00%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tyratech (DI/S) LSE:TYR London Ordinary Share COM SHS USD0.001 (DI / REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.95 2.70 3.20 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

TyraTech, Inc. Listing with Walgreens in the USA (5366J)

08/04/2015 7:00am

UK Regulatory


Tyratech (LSE:TYR)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Tyratech Charts.

TIDMTYR TIDMTYRU

RNS Number : 5366J

TyraTech, Inc.

08 April 2015

TyraTech, Inc.

("TyraTech" or the "Company")

Vamousse(R) head lice treatment now distributed by Walgreens in the USA

TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured a listing for its Vamousse Treatment product with Walgreens in the USA.

Walgreens

Through the merger of Walgreens and Alliance Boots completed in December 2014, Walgreens Boots Alliance is now the first global pharmacy-led, health and wellbeing enterprise in the world. In the USA, Walgreens is the largest pharmacy chain with more than 8,000 stores. The Walgreens listing, which follows the recent announcement of the Vamousse listing with CVS as well as with the top three pharmaceutical distributors in the USA, represents an additional key milestone for the roll-out of TyraTech's Vamousse products in the USA. It is expected that the Vamousse Treatment product will be available in the majority of Walgreens stores nationwide in the USA from May 2015.

Bruno Jactel, Chief Executive Officer, said: "The Walgreens listing, following the recent CVS listing and the listing with Walmart last year will put our Vamousse head lice treatment in three of the top four pharmacy retailers in the USA. This is a significant step in the implementation of our strategy of making our products widely available to customers and building a national brand in the US. The TyraTech team is committed, more than ever, to building a brand, expanding distribution for our Vamousse products and creating value for our shareholders.

Further information on Vamousse(R) is available on the Company's website at http://www.vamousselice.com/

 
 TyraTech Inc. 
  Bruno Jactel, Chief Executive       Tel: +1 919 
  Officer                             415 4340 
  Vincent T. Morgus, Chief            Tel: +1 919 
  Financial Officer & Treasurer       415 4287 
 SPARK Advisory Partners Limited,   Tel: +44203 
  Nominated Adviser                  368 3552 
  Matt Davis / Mark Brady            Tel: +44203 
                                     368 3551 
 Allenby Capital Limited , 
  Joint Broker                        Tel: +44 20 
  Chris Crawford                      3328 5656 
 Whitman Howard Limited, Joint 
  Broker                              Tel: +44 20 
  Ranald Mc-Gregor Smith /            7659 1240 
  Niall Devins 
 Walbrook, Financial PR and 
  IR                                  Tel: +44 20 
  Nick Rome /Guy McDougall            7933 8790 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFMGGDKNMGKZM

1 Year Tyratech Chart

1 Year Tyratech Chart

1 Month Tyratech Chart

1 Month Tyratech Chart

Your Recent History

Delayed Upgrade Clock